https://www.aigom.it/wp-content/uploads/2025/01/ART14.1.png1222960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-01-13 18:20:432025-01-13 18:20:43FINAL RESULTS FOR ADJUVANT DABRAFENIB PLUS TRAMETINIB IN STAGE III MELANOMA
https://www.aigom.it/wp-content/uploads/2025/01/ART.07.01.png1148960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-01-06 13:58:302025-01-06 13:58:30HORMONAL CONTRACEPTION AND BREAST CANCER RISK FOR CARRIERS OF GERMLINE MUTATIONS IN BRCA1 AND BRCA2
https://www.aigom.it/wp-content/uploads/2024/12/loc.trapani.png1023740Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-12-10 16:43:582024-12-10 16:43:5914 DICEMBRE 2024-TRAPANI: LA RIVOLUZIONE MULTIDISCIPLINARE NEL TRATTAMENTO DEL CARCINOMA DEL COLON-RETTO
https://www.aigom.it/wp-content/uploads/2024/12/art.10.12.png1084960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-12-09 15:42:272024-12-09 15:42:27OMISSION OF RADIOTHERAPY AFTER BREAST-CONSERVING SURGERY FOR WOMEN WITH BREAST CANCER WITH LOW CLINICAL AND GENOMIC RISK: 5-YEAR OUTCOMES OF IDEA
https://www.aigom.it/wp-content/uploads/2024/12/met2025.png659499Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-12-04 09:00:192025-01-11 10:06:45VENERDÌ 24– SABATO 25 GENNAIO 2025-NEGRAR DI VALPOLICELLA (VR) SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA
https://www.aigom.it/wp-content/uploads/2024/12/callropi.png693675Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-12-04 08:45:042024-12-04 08:45:04CALL TO ACTION-TEMPI CERTI DI ATTESA PER I PAZIENTI ONCOLOGICI: PDTA UNIFORMI E RETI EFFICIENTI
https://www.aigom.it/wp-content/uploads/2024/12/ART02.12.png1029960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-12-03 05:21:122024-12-03 05:21:12DURVALUMAB AFTER CHEMOTHERAPY IN LIMITED-STAGE SMALL-CELL LUNG CANCER.
https://www.aigom.it/wp-content/uploads/2024/11/LOC-26.11.png1227960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-26 07:14:382024-11-26 07:14:38NODAL BURDEN AND ONCOLOGIC OUTCOMES IN PATIENTS WITH RESIDUAL ISOLATED TUMOR CELLS AFTER NEOADJUVANT CHEMOTHERAPY (ypN0i+): THE OPBC-05/ICARO STUDY
https://www.aigom.it/wp-content/uploads/2024/11/LOC-19.11.png1227960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-18 17:42:362024-11-18 17:42:36UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.
https://www.aigom.it/wp-content/uploads/2024/11/LOC.12.11.png1134960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-10 14:16:252024-11-10 14:16:25CHARACTERISTICS AND CLINICAL OUTCOMES OF BREAST CANCER IN YOUNG BRCA CARRIERS ACCORDING TO TUMOR HISTOLOGY
